Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded indication for alirocumab injection for adult patients with homozygous ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In a new study, subcutaneous biweekly alirocumab, added to high-intensity statin therapy, resulted ...
Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater ...
Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor Paris and Tarrytown, New York -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that nine new Phase ...
With its new, more consumer-friendly price, use of the PCSK9 inhibitor alirocumab (Praluent; Sanofi/Regeneron) in patients with acute coronary syndrome is a relatively cost-effective option for ...
The cholesterol drug alirocumab reduced low-density lipoprotein (LDL) cholesterol by 35.6% compared to placebo in adult patients with homozygous familial hypercholesterolemia (HoFH), according to a ...
Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as ...
An experimental antibody drug could prove effective at lowering LDL ("bad") cholesterol levels for patients who have side effects with cholesterol-lowering statin medications. That's the conclusion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results